Therapeutic Programs
Undisclosed
Pre-clinicalActive
Key Facts
About Agathos Biologics
Agathos Biologics is a private, pre-revenue biotech firm developing an ethical cell line platform for biomanufacturing, specifically targeting the recombinant adeno-associated virus (rAAV) production market for gene therapies. Its core technology, the AE1-BHK cell line, is offered as an alternative to controversial HEK293 cells, aiming to address scalability and ethical concerns in the industry. The company is led by a seasoned team with deep experience in gene therapy and biomanufacturing, and it is actively pursuing internal therapeutic programs and collaborations.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |